Royalty Pharma plc RPRX

$ 24.79 2.08%

Quarterly report 2024-Q3
added 11-06-2024

Royalty Pharma plc Financial Statements 2011-2024 | RPRX

Annual Financial Statements Royalty Pharma plc

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	13.4 B	16.5 B	16.3 B	17.4 B	-	-	-	-	-	-	-	-	-
Shares	448 M	438 M	415 M	375 M	-	-	-	-	-	-	-	-	-
Historical Prices	30	37.8	39.3	46.2	-	-	-	-	-	-	-	-	-
Net Income	1.13 B	42.8 M	620 M	975 M	2.35 B	1.38 B	1.21 B	-	-	-	-	-	-
Revenue	2.35 B	2.24 B	2.29 B	2.12 B	1.79 B	1.66 B	1.58 B	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	1.49 B	307 M	1.43 B	1.6 B	2.62 B	1.36 B	-	-	-	-	-	-	-
Interest Expense	187 M	188 M	166 M	157 M	269 M	280 M	-	-	-	-	-	-	-
EBITDA	-	313 M	1.45 B	1.62 B	2.65 B	1.4 B	973 M	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-829 M	294 M	638 M	-	-	-	-	-	-
General and Administrative Expenses	250 M	227 M	183 M	182 M	103 M	61.9 M	106 M	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Royalty Pharma plc

	2024-Q3	2024-Q2	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	448 M	451 M	448 M	450 M	446 M	-	439 M	436 M	434 M	-	428 M	409 M	390 M	-	370 M	354 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	544 M	102 M	72.1 M	228 M	341 M	-	143 M	305 M	51.8 M	-	102 M	441 M	69.1 M	-	291 M	442 M	71.2 M	-	409 M	152 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	565 M	537 M	536 M	538 M	684 M	-	573 M	536 M	562 M	-	586 M	555 M	573 M	-	538 M	511 M	501 M	-	464 M	458 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	735 M	270 M	151 M	249 M	479 M	-	192 M	378 M	220 M	-	303 M	745 M	229 M	-	511 M	409 M	361 M	-	532 M	328 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-1.65 M	6 M	-1.71 M	1.09 M	47 M	-	47 M	47 M	47.1 M	-	44.3 M	37.4 M	37.4 M	-	31.4 M	34.2 M	53.6 M	-	68.8 M	69.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	192 M	378 M	225 M	-	309 M	751 M	235 M	-	516 M	415 M	367 M	-	538 M	334 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	56.7 M	54.7 M	57.2 M	47.6 M	85.7 M	-	50.7 M	51.8 M	51.5 M	-	48.6 M	44.9 M	43.2 M	-	50.7 M	42.8 M	38.1 M	-	25.6 M	30.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency